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AntioxidantAbstract A series consisting of 30 novel imidazo[4,5-b]pyridine benzohydrazones have been synthe-
sized and evaluated for their antiglycation activity as well as their antioxidative potential. The syn-
thetic part involves a 3-step reaction in which a pyridine diamine was being converted into a imidazo
[4,5-b]pyridine, which was then subjected through another reaction to yield benzohydrazide. Subse-
quently, the attained benzohydrazide of imidazo[4,5-b]pyridine was used to synthesize the target
molecules after treating them with the appropriate benzohydrazone derivatives. The derivatives were
evaluated for the antiglycation and antioxidant activities. Result obtained showed that di and trihy-
droxy substituted compounds showed good activity with compound 25 (140.16 ± 0.36 lM) having
the most potent antiglycation activity, which is twice lower than Rutin. The results also showedurnal of
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Chemistry (2015), http://dx.doi.org/10.1016/certain correlation between antiglycation activities with DPPH radical scavenging model as well as
FRAP which indicated the participation of antioxidative effect in inhibiting glycation activity.
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Glycation occurs due to reaction which occurs slowly between
reducing sugars and free amino acids. The reaction process
which is also known as Maillard reaction involves a series of
complex non-enzymatic reactions (Hodge, 1953). An interme-
diate known as Amadori product is produced in early stages of
glycation process (Goldin et al., 2006). Further, rearrangement
and reduction of this intermediate result in the production of
various advanced glycation endproducts (AGEs) such as cross-
line, pyralline, carboxyethyllysine (CEL), pentosidine, arg-
pyrimidine and carboxymethyllysine (CML) (Obayashia
et al., 1996; Heijst et al., 2005; Zhang et al., 2011). Glycation
is a haphazard process which can take place endogenously
(Kellow and Savige, 2013). Glycation which occurs in body
could modify biomolecules such as lens crystallins, collagen,
hemoglobin (Hb), albumin, Igs, LDL and DNA (Misciagna
et al., 2007). The modification leads to impaired protein func-
tion (Goodarzi et al., 2010) and perhaps contributes to
microvascular disease which slows down wound healing for
diabetic patients (Rodriguez and Jarvis, 2012). Oxidation of
Amadori product produces other intermediates which could
react with a free amino group nearby and form crosslinking
between proteins (Ulrich and Cerami, 2000). The crosslinking
which occurs in protein such as collagen causes arterial stiff-
ness and decreased myocardial compliance and it is often
found in aging patients having diabetes (Singh et al., 2001;
Aronson, 2003). Thus, agents have antioxidative effect against
production of Amadori product and are capable of inhibiting
the production of AGEs would potentially be used to treat
patients with age-related diseases and diabetes.
In the present study, a library of compounds consisting of
imidazopyridine scaffold had been synthesized. Imidazo[4,5-b]
pyridine which contains a fused imidazole ring had been
reported for various activities such as b-glucuronidase (Taha
et al., 2015a; Zawawi et al., 2015;), anticancer (Temple et al.,
1987), antitubecular (Bukowski and Kaliszan, 1991), antiglyca-
tion (Taha et al., 2014a), and antioxidant (Lavanya et al.,
2011). Through this study, we have discovered some novel
imidazo[4,5-b]pyridine derivatives showing potent activity
against both antiglycation and antioxidation activities. Our
research was inspired by the fact that compounds having imida-
zole possess versatile biological properties and easily interact
with the nature (Narasimhan et al., 2011). Compounds having
fused imidazole ring, had been reported for various activities
such as urease inhibition (Saify et al., 2014), antibacterial
(Vijesh et al., 2011), anticancer (Yang et al., 2012), antitubecu-
lar (Lee et al., 2011) and analgesics (Uc¸ucu et al., 2001) activi-
ties. Imidazole had also been reported to show in vivo
antihyperglycemic activity for the treatment of type 2 diabetes
mellitus by stimulating insulin secretion and decreasing insulin
resistance of peripheral tissues via reduction of hyperglycemia
(Plant and Henquin, 1990; Crane et al., 2006). Interestingly,
imidazole moiety is also considered significant for antiglycationet al., Antiglycation and antioxidant p
j.arabjc.2015.08.004activity as it was found that, free amino group of imidazole ring
will competes with amine side groups of proteins in the presence
of reactive dicarbonyl compounds (Brownson and Hipkiss,
2000). Benzohydrazides are reported to possess a broad variety
of biological activities such as antiglycation (Khan et al., 2013a,
b and Khan et al., 2015; Jamil et al., 2015), antioxidant (Aziz
et al., 2014; Khan et al., 2012), antileishmanial (Taha et al.,
2014b), antibacterial (Imran et al., 2014), b-glucuronidase
(Jamil et al., 2014), urease (Taha et al., 2015b and c) and
a-glucosidase (Taha et al., 2015f).
In the light of literature review, benzimidazole as well as
benzohydrazide derivatives are found to have potent
activity of antiglycation as well as antioxidant. We
synthesized compounds which have imidazo[4,5-b]pyridine
ring as well as benzohydrazide in order to see the combined
effect of both classes on antioxidant as well as antiglycation
activity.
2. Experimental
2.1. General
NMR experiments were performed on UltraShield Bruker FT
NMR 500 MHz; CHN analysis was performed on a Carlo
Erba Strumentazion-Mod-1106, Italy. Electron impact mass
spectra (EI-MS) were recorded on a Finnegan MAT-311A,
Germany. Thin layer chromatography (TLC) was performed
on pre-coated silica gel aluminum plates (Kieselgel 60, 254,
E. Merck, Germany). Chromatograms were visualized by
UV at 254 and 365 nm.
2.2. Antioxidant
2.2.1. DPPH radical scavenging assay
The free radical scavenging activity was measured by 1,1-
diphenyl-2-picrylhydrazil (DPPH) using literature protocols.
Reaction mixture contains 5 lL of test sample (1 mM in
DMSO) and 95 lL of DPPH (Sigma, 300 lM) in ethanol.
The reaction mixture was incubated at 37 C for 30 min. The
absorbance was measured at 515 nm on microtiter plate reader
(Molecular Devices, CA, USA). Percent radical scavenging
activity was determined in comparison with a DMSO contain-
ing control. IC50 values represent the concentration of com-
pounds to scavenge 50% of DPPH radicals. Propyl gallate
was used as a positive control. All the chemicals used were
of analytical grade (Sigma, USA).
2.2.2. FRAP assay
FRAP reagent was prepared freshly by mixing 2.5 ml of solu-
tions TPTZ (10 mM, dissolved in 40 mM HCl) and FeCl3
(20 mM) in 25 ml of acetate buffer (300 mM concentration
and pH 3.6), and the light blue reagent contains Fe3+–TPTZ
that changes to dark blue after interaction with antioxidants,otential of novel imidazo[4,5-b]pyridine benzohydrazones. Arabian Journal of
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reagent. These changes were due to the absorbance increase
as monitored at a wavelength of 593 nm. The standard calibra-
tion curve was obtained by using different concentrations of
FeSO47H2O as standard for calculation of the FRAP values
for both Quercetin and complex.
2.3. Antiglycation
Bovine Serum Albumin (BSA) was purchased from Merck
Marker Pvt. Ltd. (Germany), rutin and methylglyoxal (MG)
(40% aqueous solution) were from Sigma Aldrich (Japan),
and sodium dihydrogen phosphate (NaH2PO4), disodium
hydrogen phosphate (Na2HPO4) and sodium azide (NaN3)
were purchased from Scharlau Chemie, S.A. (Spain), while
dimethyl sulphoxide (DMSO) was purchased from Fischer Sci-
entific (UK). Bovine Serum Albumin (10 mg/mL), methyl gly-
oxal (14 mM), various concentrations of the compounds
(prepared in DMSO, 10% final concentration), and 0.1 M
phosphate buffer (pH 7.4) containing sodium azide (30 mM)
were incubated under aseptic conditions at 37 C for 9 days.
After 9 days, each sample was examined for the development
of specific fluorescence (excitation, 330 nm; emission,
440 nm) against sample blank. Rutin was used as a positive
control. The percent inhibition of AGE formation in the test
sample versus control was calculated for each inhibitor com-
pound by using the following formula: % inhibition = (1- flu-
orescence of test sample/fluorescence of the control group) 
100.
2.4. Synthesis of methyl 4-(6-chloro-3H-imidazo[4,5-b]pyridin-
2-yl)benzoate (3)
5-Chloropyridine-2,3-diamine (1) (7.58 g, 53 mmol) and 4-
formylbenzoic acid methyl ester (2) (6.73 g, 41 mmol) were dis-
solved in DMF (40 mL) refluxed at 130 C for 6 h. Then reac-
tion mixture was poured into ice water and the solid product
was filtered, crystallization of crude product from ethanol gave
methyl 4-(6-chloro-3H-imidazo[4,5-b]pyridin-2-yl)benzoate (3)
and yielded 14.1 g (93%). White solid, m.p. 228 C. 1H NMR
(400 MHz, DMSO-d6): d 11.60 (s, 1H), 8.50 (d, J= 8.0 Hz,
1H), 7.92 (d, J= 8.0 Hz, 1H), 7.88 (d, J= 8.5 Hz, 2H), 7.68
(d, J= 8.5 Hz, 2H), 3.85 (s, 3H, CH3);
13C NMR (DMSO-
d6, 125 MHz): d 167.3, 152.2, 145.1, 139.9, 133.2, 131.7,
129.4, 129.4, 128.3, 127.09, 126.2, 126.2, 124.4, 52.0; Anal.
Calcd for C14H10ClN3O2, C = 58.45, H = 3.50, N = 14.61;
found C = 58.47, H = 3.49, N = 14.59; EI MS m/z (% rel.
abund.): 287 (M+, 62), 289 (M+2, 24).
2.5. 4-(6-chloro-3H -imidazo[4,5-b]pyridin-2-yl)
benzohydrazide (4)
A mixture of compound 3 (11.48 g, 40 mmol) and hydrazine
hydrate (15 mL, 95%) in ethanol (50 mL) was refluxed for
12 h. The solvent and excess of hydrazine hydrate were evapo-
rated and the residue (4) was washed with water, filtered, dried,
and then crystallized from ethanol and gives white solid,
(10.8 g, 94%). m.p. 315 C. 1H NMR (500 MHz, DMSO-d6):
d 11.60 (s, 1H), 11.10 (s, 1H), 8.51 (d, J= 8.0 Hz, 1H), 7.91
(d, J= 8.0 Hz, 1H), 7.87 (d, J= 8.5 Hz, 2H), 7.69 (d,
J= 8.5 Hz, 2H), 4.15 (br. s, 2H, NH2);
13C-NMRPlease cite this article in press as: Taha, M. et al., Antiglycation and antioxidant p
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133.6, 131.7, 128.5, 128.5, 128.3, 126.5, 126.5, 124.4; Anal.
Calcd for C13H10ClN5O, C = 54.27; H = 3.50; N = 24.34;
found C = 54.28; H = 3.48; N = 24.35; EI MS m/z (% rel.
abund.): 287 (M+, 72), 289 (M+2, 26).
2.6. General procedure for synthesis of imidazo[4,5-b]pyridine
benzohydrazones (5–34)
Equimolar quantities (0.332 g, 1 mmol) of imidazo[4,5-b]pyri-
dine benzohydrazide (4) and substituted benzaldehydes
(1 mmol) in methanol (25 mL) were refluxed for 3 h, in the
presence of catalytic amount of glacial acetic acid. The result-
ing solid was filtered and recrystallized from methanol in good
yields.
2.6.1. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-(2-
hydroxy-5-methoxybenzylidene) benzohydrazide (5)
Orange solid, m.p. 270 C. Yield: (0.345 g, 82%); 1H NMR
(400 MHz, DMSO-d6): d 12.20 (s, 1H), 10.63 (s, 1H), 8.66 (s,
1H), 8.46 (s, 1H), 8.36–8.38 (m, 3H), 8.13 (d, J= 8.4 Hz,
2H), 7.15 (d, J= 2.8 Hz, 1H), 6.86 (m, 2H), 3.74 (s, 3H);
13C NMR (125 MHz, DMSO-d6): d 164.3, 154.4, 154.3,
149.6, 148.8, 148.1, 143.3, 136.1, 134.0, 130.4, 129.3, 129.3,
127.2, 127.2, 126.2, 121.7, 116.5, 116.5, 116.3, 112.8, 56.0;
Anal. Calcd for C21H16ClN5O3, C = 59.79, H = 3.82,
N = 16.60 = Found C = 59.77, H = 3.85, N = 16.63; EI
MS m/z (% rel. abund.): 421 (M+, 78), 423 (M+2, 25).
2.6.2. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-
(pyridin-2-ylmethylene) benzohydrazide (6)
Light yellow solid, m.p. 285 C. Yield: (0.327 g, 87%); 1H
NMR (400 MHz, DMSO-d6): d 12.15 (s, 1H), 8.88 (s, 1H),
8.62 (d, J= 4.0 Hz, 1H), 8.53 (s, 1H), 8.46 (s, 1H), 8.36–8.39
(m, 3H), 8.11 (m, 3H), 7.51 (t, J= 4.8 Hz, 1H); 13C NMR
(125 MHz, DMSO-d6): d 164.3, 154.7, 148.8, 148.0, 146.9,
146.0, 142.7, 137.6, 136.1, 134.0, 130.4, 129.5, 129.3, 129.3,
127.2, 127.2, 124.1, 123.0, 119.0; Anal. Calcd for
C19H13ClN6O, C = 60.56; H = 3.48; N = 22.30, Found
C = 60.58; H = 3.51; N = 22.27; EI MS m/z (% rel. abund.):
376 (M+, 67), 378 (M+2, 23).
2.6.3. (E)-4-(6-chloro-1H-imidazo[4,5- b]pyridin-2-yl)-N0-
(pyridin-3-ylmethylene) benzohydrazide (7)
White solid, m.p. 265 C. Yield: (0.293 g, 78%); 1H NMR
(400 MHz, DMSO-d6): d 12.21 (s, 1H), 8.63 (d, J= 4.0 Hz,
1H), 8.51(s, 1H), 8.46 (s, 1H), 8.33–8.40 (m, 3H), 8.12 (d,
J= 8.0 Hz, 2H), 8.00 (d, J= 8.0 Hz, 1H), 7.90(t,
J= 7.2 Hz, 1H), 7.42 (t, J= 5.2 Hz, 1H); 13C NMR
(125 MHz, DMSO-d6): d 164.3, 149.8, 148.8, 146.9, 146.3,
145.5, 142.7, 136.1, 135.6, 134.0, 133.8, 130.4, 129.5, 129.3,
129.3, 127.3, 127.3, 124.4, 124.1; Anal. Calcd for C19H13ClN6-
O, C = 60.56; H = 3.48; N = 22.30, Found C = 60.55;
H = 3.50; N = 22.28; EI MS m/z (% rel. abund.): 376 (M
+, 69), 376 (M+2, 20).
2.6.4. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-(4-
hydroxybenzylidene) benzohydrazide (8)
White solid, m.p. 298 C. Yield: (0.344 g, 88%); 1H NMR
(400 MHz, DMSO-d6): d 11.77 (s, 1H), 9.94(s, 1H), 8.46 (s,otential of novel imidazo[4,5-b]pyridine benzohydrazones. Arabian Journal of
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J= 8.4 Hz, 2H), 6.84 (d, J= 8.4 Hz, 2H); 13C NMR
(125 MHz, DMSO-d6): d 164.3, 158.3, 149.3, 148.8, 146.9,
142.7, 136.1, 134.0, 130.4, 129.7, 129.7, 129.5, 129.2, 129.2,
127.3, 127.3, 126.9, 124.1, 115.6, 115.6; Anal. Calcd for
C20H14ClN5O2, C = 61.31, H = 3.60, N = 17.87, Found
C = 61.33, H = 3.59, N = 17.89, EI MS m/z (% rel. abund.):
391 (M+, 56), 393 (M+2, 21).
2.6.5. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-
(thiophen-2-ylmethylene) benzohydrazide (9)
Light orange solid, m.p. 268 C. Yield: (0.316 g, 83%); 1H
NMR (300 MHz, DMSO-d6): d 13.86 (s, 1H), 11.93 (s, 1H),
8.68 (s, 1H), 8.46 (d, J= 2.0 Hz, 1H), 8.35–8.37 (m, 3H),
8.07 (d, J= 8.4 Hz, 2H), 7.69 (d, J= 6.8 Hz, 1H), 7.49 (d,
J= 4.0 Hz, 1H), 7.69 (t, J= 5.6 Hz, 1H); 13C NMR
(125 MHz, DMSO-d6): d 164.3, 148.8, 146.9, 142.7, 138.8,
136.1, 134.0, 132.9, 131.7, 130.4, 129.5, 129.2, 129.2, 128.8,
128.3, 127.2, 127.2, 124.1; Anal. Calcd for C18H12ClN5OS,
C = 56.62, H = 3.17, N = 18.34, Found C = 56.64,
H = 3.19, N = 18.33; EI MS m/z (% rel. abund.): 381 (M
+, 74), 383 (M+2, 26).
2.6.6. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-
(2,3-dihydroxybenzylidene) benzohydrazide (10)
White solid, m.p. 274 C. Yield: (0.346 g, 85%); 1H NMR
(300 MHz, DMSO-d6): d 13.85 (s, 1H), 12.23 (s, 1H), 11.06
(s, 1H), 9.24 (s, 1H), 8.63 (s, 1H), 8.46 (s, 1H), 8.27–8.39 (m,
3H), 8.12 (d, J= 8.1 Hz, 2H), 6.98 (d, J= 7.5 Hz, 1H), 6.85
(d, J= 6.9 Hz, 1H), 6.72 (t, J= 7.8 Hz, 1H); 13C NMR
(125 MHz, DMSO-d6): d 164.3, 149.9, 148.8, 146.9, 146.9,
144.6, 142.7, 136.1, 134.0, 130.4, 129.5, 129.2, 129.2, 127.2,
127.2, 124.1, 122.0, 121.3, 119.9, 119.8; Anal. Calcd for
C20H14ClN5O3, C = 58.90, H = 3.46, N = 17.17; Found
C = 58.92, H = 3.45, N = 17.18; EI MS m/z (% rel. abund.):
407 (M+, 48), 409 (M+2, 13).
2.6.7. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-
(3,4,5-trihydroxybenzylidene) benzohydrazide (11)
Yellowish solid, m.p. 282 C. Yield: (0.368 g, 87%); 1H NMR
(300 MHz, DMSO-d6): d 13.84 (s, 1H), 11.69 (s, 1H), 9.13 (s,
2H), 8.60 (s, 1H), 8.45 (s, 1H), 8.34–8.28 (m, 3H), 8.19 (s,
1H), 8.06 (d, J= 8.4 Hz, 2H), 6.70 (s, 2H); 13C NMR
(125 MHz, DMSO-d6): d 164.3, 148.8, 148.1, 148.1, 147.9,
146.9, 142.7, 136.1, 135.9, 134.0, 130.4, 129.5, 129.2, 129.2,
128.2, 127.2, 127.2, 124.1, 109.2, 109.2; Anal. Calcd for
C20H14ClN5O4, C = 56.68, H = 3.33, N = 16.52, Found
C = 56.69, H = 3.34, N = 16.50; EI MS m/z (% rel. abund.):
423 (M+, 58), 425 (M+2, 21).
2.6.8. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-(2-
hydroxybenzylidene) benzohydrazide (12)
White solid, m.p. 281 C. Yield: (0.282 g, 72%); 1H NMR
(300 MHz, DMSO-d6): d 13.90 (s, 1H), 12.24 (s, 1H), 11.21
(s, 1H), 8.67 (s, 1H), 8.46 (s 1H), 8.39 (s 1H), 8.36 (s 1H),
8.14 (d, J= 8.4 Hz, 2H), 7.59 (d, J= 7.2 Hz, 1H); 7.34 (t,
J= 7.1 Hz, 1H) 6.95 (d, J= 7.2 Hz, 2H); 13C NMR
(125 MHz, DMSO-d6): d 164.3, 158.3, 151.0, 148.8, 146.9,
142.7, 136.1, 134.0, 130.4, 129.7, 129.5, 129.3, 129.3, 128.5,
127.1, 127.1, 124.1, 121.1, 120.3, 117.3; Anal. Calcd for
C20H14ClN5O2, C = 61.31, H = 3.60, N = 17.87, FoundPlease cite this article in press as: Taha, M. et al., Antiglycation and antioxidant p
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391 (M+, 48), 393 (M+2, 13).
2.6.9. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-
(furan-2-ylmethylene)benzohydrazide (13)
Light yellow solid, m.p. 268 C. Yield: (0.327 g, 89%); 1H
NMR (300 MHz, DMSO-d6): d 13.95 (s, 1H), 11.92 (s, 1H),
8.44 (s, 1H), 8.36 (m, 4H), 8.07–8.22 (m, 2H), 7.87 (s, 1H),
6.96 (d, J= 4.0 Hz, 1H), 6.65 (s, 1H); 13C NMR (125 MHz,
DMSO-d6): d 164.3, 148.8, 148.3, 146.9, 144.9, 142.7, 137.3,
136.1, 134.0, 130.4, 129.5, 129.1, 129.1, 127.2, 127.2, 124.1,
120.7, 112.8; Anal. Calcd for C18H12ClN5O2, C = 59.11,
H = 3.31, N = 19.15, Found C = 59.13, H = 3.30,
N = 19.17; EI MS m/z (% rel. abund.): 365 (M+, 53), 367
(M+2, 18).
2.6.10. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-
(3,4-dihydroxybenzylidene) benzohydrazide (14)
White solid, m.p. 279 C. Yield: (0.346 g, 85%); 1H NMR
(400 MHz, DMSO-d6): d 11.72 (s, 1H), 9.39 (s, 1H), 9.27 (s,
1H), 8.46 (s, 1H), 8.28–8.25 (m, 4H), 8.08 (d, J= 8.4 Hz,
2H), 7.26 (s, 1H), 6.94 (d, J= 7.2 Hz, 1H), 6.78 (d,
J= 8.0 Hz, 1H); 13C NMR (125 MHz, DMSO-d6): d 164.3,
148.8, 148.6, 148.1, 146.9, 145.5, 142.7, 136.1, 134.0, 130.4,
129.5, 129.3, 129.3, 127.9, 127.2, 127.2, 124.1, 121.0, 116.6,
115.9; Anal. Calcd for C20H14ClN5O3, C = 58.90, H = 3.46,
N = 17.17; Found C = 58.91, H = 3.48, N = 17.19; EI MS
m/z (% rel. abund.): 407 (M+, 62), 409 (M+2, 22).
2.6.11. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-
(2,4-dihydroxybenzylidene) benzohydrazide (15)
Orange solid, m.p. 286 C. Yield: (0.374 g, 92%); 1H NMR
(300 MHz, DMSO-d6): d 13.89 (s, 1H), 12.04 (s, 1H), 11.41
(s, 1H), 9.98 (s, 1H), 8.53 (s, 1H), 8.46 (s, 1H), 8.35–8.38 (m,
3H), 8.10 (d, J= 8.4 Hz, 2H), 7.32 (d, J= 8.4 Hz, 1H), 6.36
(dd, J= 2.1 Hz, 8.7 Hz, 1H), 6.36 (d, J= 2.1 Hz, 1H); 13C
NMR (125 MHz, DMSO-d6): d 164.3, 160.5, 160.5, 151.0,
148.8, 146.9, 142.7, 136.1, 134.0, 130.8, 130.4, 129.5, 129.2,
129.2, 127.3, 127.3, 124.1, 113.1, 109.2, 103.0; Anal. Calcd
for C20H14ClN5O3, C = 58.90, H = 3.46, N = 17.17; Found
C = 58.89, H = 3.47, N = 17.15; EI MS m/z (% rel. abund.):
407 (M+, 46), 409 (M+2, 17).
2.6.12. (E)-methyl4-((2-(4-(6-chloro-1H-imidazo[4,5-b]
pyridin-2-yl)benzoyl)hydrazono)methyl) benzoate (16)
Light orange solid, m.p. 281 C. Yield: (0.355 g, 82%); 1H
NMR (300 MHz, DMSO-d6): d 12.16 (s, 1H), 8.53 (s, 1H),
8.45 (s, 1H), 8.37 (d, J= 8.1 Hz, 2H), 8.11 (d, J= 8.4 Hz,
2H), 8.05 (d, J= 8.1 Hz, 2H), 7.89 (d, J= 8.1 Hz, 2H); 13C
NMR (125 MHz, DMSO-d6): d 167.3, 164.3, 149.3, 148.8,
146.9, 142.7, 137.5, 136.1, 134.5, 134.0, 130.4, 129.5, 129.3,
129.3, 128.3, 128.3, 127.6, 127.6, 127.3, 127.3, 124.1, 52.0;
Anal. Calcd for C22H16ClN5O3, C = 60.91, H = 3.72,
N = 16.14, Found C = 60.90, H = 3.74, N = 16.16; EI MS
m/z (% rel. abund.): 433 (M+, 72), 435 (M+2, 25).
2.6.13. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-
(3,4-dimethoxybenzylidene) benzohydrazide (17)
White solid, m.p. 258 C. Yield: (0.339 g, 78%); 1H NMR
(400 MHz, DMSO-d6): d 11.85 (s, 1H), 8.46 (s, 1H), 8.40 (s,otential of novel imidazo[4,5-b]pyridine benzohydrazones. Arabian Journal of
Novel imidazo[4,5-b]pyridine benzohydrazones 51H), 8.35 (d, J= 8.4 Hz, 2H), 8.08 (d, J= 8.0 Hz, 2H), 7.36
(s, 1H), 7.22 (d, J= 8.0 Hz, 1H), 7.03 (d, J= 8.0 Hz, 1H),
3.81 (s, 6H); 13C NMR (125 MHz, DMSO-d6): d 164.3,
150.4, 149.7, 148.8, 148.6, 146.9, 142.7, 136.1, 134.0, 130.4,
129.5, 129.3, 129.2, 129.2, 127.3, 127.3, 124.1, 122.1, 114.1,
110.0, 60.2, 56.7; Anal. Calcd for C22H18ClN5O3, C = 60.62,
H = 4.16, N = 16.07, Found C = 60.60, H = 4.17,
N = 16.05; EI MS m/z (% rel. abund.): 435 (M+, 39), 437
(M+2, 13).
2.6.14. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-(4-
nitrobenzylidene)benzohydrazide (18)
Yellow solid, m.p. 278 C. Yield: (0.365 g, 87%); 1H NMR
(400 MHz, DMSO-d6): d 12.28 (s, 1H), 8.58 (s, 1H), 8.46 (s,
1H), 8.31–8.39 (m, 5H), 8.12 (d, J= 8.0 Hz, 2H), 8.01 (d,
J= 8.0 Hz, 2H); 13C NMR (125 MHz, DMSO-d6): d 164.3,
149.3, 148.8, 148.1, 148.0, 143.3, 139.9, 136.1, 134.0, 130.4,
129.3, 129.3, 127.8, 127.8, 127.2, 127.2, 126.2, 124.3, 124.3,
116.5; Anal. Calcd for C20H13ClN6O3, C = 57.08, H = 3.11,
N = 19.97, Found C = 57.09, H = 3.12, N = 19.95; EI MS
m/z (% rel. abund.): 420 (M+, 54), 422 (M+2, 21).
2.6.15. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-(3-
hydroxy-4-methoxybenzylidene) benzohydrazide (19)
White solid, m.p. 274 C. Yield: (0.392 g, 93%); 1H NMR
(400 MHz, DMSO-d6): d 13.82 (s, 2H), 11.78 (s, 1H), 9.30 (s,
1H), 8.45 (s, 1H), 8.33–8.37 (m, 3H), 8.09 (d, J= 8.0 Hz,
2H), 7.29 (s, 1H), 7.07 (d, J= 8.0 Hz, 1H), 6.97 (d,
J= 8.4 Hz, 1H), 3.81 (s, 3H): 13C NMR (125 MHz, DMSO-
d6):d 164.3, 149.9, 148.8, 148.6, 146.9, 146.6, 142.7, 136.1,
134.0, 130.4, 129.5, 129.5, 129.3, 129.3, 127.2, 127.2, 124.1,
120.3, 115.2, 115.1, 56.7; Anal. Calcd for C21H16ClN5O3,
C = 59.79, H = 3.82, N = 16.60, Found C = 59.81,
H = 3.83, N = 16.58; EI MS m/z (% rel. abund.): 421 (M
+, 71), 423 (M+2, 18).
2.6.16. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-(4-
fluorobenzylidene)benzohydrazide (20)
Light orange solid, m.p. 263 C. Yield: (0.322 g, 82%); 1H
NMR (300 MHz, DMSO-d6): d 13.86 (s, 1H), 11.99 (s, 1H),
8.48 (d, J= 8.4 Hz, 2H), 8.35–8.38 (m, 3H), 8.10 (d,
J= 8.1 Hz, 2H), 7.80 (t, J= 7.5 Hz, 2H), 7.32 (t,
J= 9.3 Hz, 2H); 13C NMR (125 MHz, DMSO-d6): d 164.3,
161.2 (d, J= 262.0 Hz), 149.3, 148.8, 146.9, 142.7, 136.1,
134.0, 130.7, 130.4, 130.2, 130.2, 129.5, 129.2, 129.2, 127.2,
127.2, 124.1, 115.3, 115.3; Anal. Calcd for C20H13ClFN5O,
C = 61.00, H = 3.33, N = 17.78, Found C = 61.02,
H = 3.35, N = 17.77; EI MS m/z (% rel. abund.): 393 (M
+, 86), 395 (M+2, 34).
2.6.17. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-
(2,5-dimethoxybenzylidene) benzohydrazide (21)
Light yellow solid, m.p. 256 C. Yield: (0.396 g, 91%); 1H
NMR (400 MHz, DMSO-d6): d 11.99 (s, 1H), 8.46 (s, 1H),
8.36–8.41 (m, 4H), 8.09 (d, J= 8.0 Hz, 2H), 6.90 (s, 2H),
6.59 (s, 1H), 3.80 (s, 3H); 13C NMR (125 MHz, DMSO-d6):
d 164.3, 154.8, 153.7, 149.2, 148.8, 148.1, 143.3, 136.1, 134.0,
130.4, 129.3, 129.3, 127.2, 127.2, 126.2, 125.9, 116.5,
115.7, 113.5, 112.7, 56.7, 56.0; Anal. Calcd for C22H18ClN5O3,
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435 (M+, 75), 437 (M+2, 25).
2.6.18. (E)-N0-benzylidene-4-(6-chloro-1H-imidazo[4,5-b]
pyridin-2-yl)benzohydrazide (22)
White crystalline solid, m.p. 278 C. Yield: (0.326 g, 87%); 1H
NMR (400 MHz, DMSO-d6): d 11.98 (s, 1H), 8.47 (d,
J= 12.0 Hz, 2H), 8.37 (d, J= 8.0 Hz, 2H), 8.11 (d,
J= 8.0 Hz, 2H), 7.75 (d, J= 8.5 Hz, 2H), 7.46–7.48 (m,
3H); 13C NMR (125 MHz, DMSO-d6): d 164.3, 149.3, 148.8,
146.9, 142.7, 136.1, 134.7, 134.0, 130.4, 129.5, 129.4, 129.4,
129.0, 129.0, 128.7, 127.2, 127.2, 127.0, 127.0, 124.1; Anal.
Calcd for C20H14ClN5O, C = 63.92, H = 3.75, N = 18.64,
Found C = 63.94, H = 3.74, N = 18.63; EI MS m/z (% rel.
abund.): 375 (M+, 36), 377 (M+2, 13).
2.6.19. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-(3-
bromo-4-fluorobenzylidene) benzohydrazide (23)
Orange solid, m.p. 274 C. Yield: (0.364 g, 77%); 1H NMR
(300 MHz, DMSO-d6): d 13.84 (s, 1H), 12.13 (s, 1H), 8.45 (s,
2H), 8.32–8.38 (m, 3H), 8.09–8.11 (m, 3H), 7.82 (s, 1H), 7.46
(t, J= 9.3 Hz, 1H); 13C NMR (125 MHz, DMSO-d6): d
164.33, 157.4 (d, J= 243 Hz), 156.4, 148.8, 148.6, 148.1,
143.3, 136.1, 134.0, 132.8, 130.4, 130.1, 129.1, 129.1, 128.6,
127.2, 127.2, 126.2, 116.5, 110.1; Anal. Calcd for C20H12
BrClFN5O, C = 50.82, H = 2.56, N = 14.82, Found
C = 50.83, H = 2.54, N = 14.81; EI MS m/z (% rel. abund.):
473 (M+, 62), 475 (M+2, 19).
2.6.20. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-(4-
methoxybenzylidene) benzohydrazide (24)
White solid, m.p. 274 C. Yield: (0.358 g, 88%); 1H NMR
(400 MHz, DMSO-d6): d 11.84 (s, 1H), 12.13 (s, 1H), 8.46 (s,
1H), 8.42 (s, 1H), 8.35–8.37 (m, 3H), 8.09 (d, J= 8.0 Hz,
2H), 7.68 (d, J= 8.4 Hz, 2H), 7.04 (d, J= 8.8 Hz, 2H), 3.82
(s, 3H); 13C NMR (125 MHz, DMSO-d6): d 164.3, 160.1,
149.3, 148.8, 146.9, 142.7, 136.1, 134.0, 130.4, 129.5, 129.4,
127.4, 129.1, 127.3, 127.3, 127.0, 124.1, 114.3, 56.0; Anal.
Calcd for C21H16ClN5O2, C = 62.15, H = 3.97, N = 17.26,
Found C = 62.17, H = 3.96, N = 17.25; EI MS m/z (% rel.
abund.): 405 (M+, 67), 407 (M+2, 25).
2.6.21. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-
(2,4,6-trihydroxybenzylidene) benzohydrazide (25)
White solid, m.p. 297 C. Yield: (0.368 g, 87%); 1H NMR
(400 MHz, DMSO-d6): d 13.93 (s, 1H), 12.01 (s, 1H), 11.09
(s, 1H), 9.83 (s, 1H), 8.83 (s, 1H), 8.35–8.50 (m, 4H), 8.10–
8.22 (m, 2H), 5.85 (s, 2H); 13C NMR (125 MHz, DMSO-d6):
d 164.3, 163.2, 161.4, 161.4, 148.8, 146.9, 144.7, 142.7, 136.1,
134.0, 130.4, 129.5, 129.3, 129.3, 127.1, 127.1, 124.1, 106.7,
94.7, 94.7; Anal. Calcd for C20H14ClN5O4, C = 56.68,
H = 3.33, N = 16.52, Found C = 56.67, H = 3.31,
N = 16.54; EI MS m/z (% rel. abund.): 423 (M+, 45), 425
(M+2, 17).
2.6.22. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-(3-
bromo-4-hydroxybenzylidene) benzohydrazide (26)
Brown solid, m.p. 284 C. Yield: (0.394 g, 84%); 1H NMR
(400 MHz, DMSO-d6): d 11.90 (s, 1H), 8.46 (s, 1H), 8.34–
8.37 (m, 4H), 8.27 (d, J= 8.4 Hz, 1H), 8.08 (d, J= 8.4 Hz,otential of novel imidazo[4,5-b]pyridine benzohydrazones. Arabian Journal of
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J= 8.4 Hz, 1H), 7.02 (d, J= 8.4 Hz, 1H); 13C NMR
(125 MHz, DMSO-d6): d 164.3, 153.7, 148.8, 148.6, 146.9,
142.7, 136.1, 134.0, 130.4, 130.4, 129.5, 129.2, 129.2, 128.4,
127.3, 127.3, 127.1, 124.1, 116.3, 109.9; Anal. Calcd for
C21H13BrClN5O2, C = 51.03; H = 2.78; N = 14.88, Found
C = 51.05; H = 2.79; N = 14.86; EI MS m/z (% rel. abund.):
471 (M+, 53), 473 (M+2, 19).
2.6.23. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-(4-
chlorobenzylidene)benzohydrazide (27)
Yellow solid, m.p. 245 C. Yield: (0.372 g, 91%); 1H NMR
(400 MHz, DMSO-d6): d 12.04 (s, 1H), 8.46 (d, J= 6.0 Hz,
2H), 8.36–8.38 (m, 3H), 8.10 (d, J= 8.0 Hz, 2H), 7.77 (d,
J= 8.4 Hz, 2H), 7.53 (d, J= 8.0 Hz, 2H); 13C NMR
(125 MHz, DMSO-d6): d 164.3, 149.3, 148.8, 148.1, 143.3,
136.1, 135.1, 134.1, 134.0, 130.4, 129.3, 129.3, 129.2, 129.2,
129.1, 129.1, 127.3, 127.3, 126.2, 116.5; Anal. Calcd for
C20H13Cl2N5O, C = 58.55, H = 3.19, N = 17.07, Found
C = 58.57, H = 3.21, N = 17.08; EI MS m/z (% rel. abund.):
409 (M+, 47), 411 (M+2, 13).
2.6.24. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-(3-
methoxybenzylidene) benzohydrazide (28)
White solid, m.p. 278 C. Yield: (0.341 g, 94%); 1H NMR
(400 MHz, DMSO-d6): d 11.98 (s, 1H), 8.46 (s, 2H), 8.33–
8.38 (m, 3H), 8.09 (d, J= 8.0 Hz, 2H), 7.37 (t, J= 8.0 Hz,
1H), 7.30 (d, J= 7.0 Hz, 2H), 7.02 (d, J= 6.8 Hz, 1H), 3.82
(s, 3H); 13C NMR (125 MHz, DMSO-d6): d 164.3, 160.2,
148.8, 148.6, 146.9, 142.7, 137.0, 136.1, 134.0, 130.4, 129.5,
129.2, 129.2, 129.2, 127.2, 127.2, 124.1, 121.2, 114.8, 112.1,
56.0; Anal. Calcd for C21H16ClN5O2, C = 62.15, H = 3.97,
N = 17.26, Found C = 62.16, H = 3.95, N = 17.27; EI MS
m/z (% rel. abund.): 405 (M+, 73), 407 (M+2, 24).Scheme 1 Synthesis of imidazo[4
Scheme 2 Synthesis of novel imidazo[4
Please cite this article in press as: Taha, M. et al., Antiglycation and antioxidant p
Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.08.0042.6.25. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-(3-
hydroxybenzylidene) benzohydrazide (29)
White crystalline solid, m.p. 272 C. Yield: (0.326 g, 83%); 1H
NMR (300 MHz, DMSO-d6): d 13.82 (s, 1H), 11.92 (s, 1H),
9.64 (s, 1H), 8.45 (s, 1H), 8.32–8.38 (m, 4H), 8.09 (d,
J= 8.1 Hz, 2H), 7.22–7.29 (m, 2H), 7.11 (d, J= 7.2 Hz,
1H), 6.83 (d, J= 7.8 Hz, 1H); 13C NMR (125 MHz, DMSO-
d6): d 164.3, 156.7, 148.8, 148.6, 146.9, 142.7, 137.0, 136.1,
134.0, 130.6, 130.4, 129.5, 129.2, 129.2, 127.1, 127.1, 124.1,
120.0, 119.3, 114.7; Anal. Calcd for C20H14ClN5O2,
C = 61.31, H = 3.60, N = 17.87, Found C = 61.29,
H= 3.62, N = 17.86; EI MS m/z (% rel. abund.): 391 (M+,
65), 393 (M+2, 20).
2.6.26. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-
(pyridin-4-ylmethylene) benzohydrazide (30)
White solid, m.p. 287 C. Yield: (0.316 g, 84%); 1H NMR
(400 MHz, DMSO-d6): d 12.24 (s, 1H), 8.66 (s, 2H), 8.46 (s,
2H), 8.33–8.38 (m, 3H), 8.11 (d, J= 8.0 Hz, 2H), 7.32 (s,
2H), 7.68 (d, J= 4.0 Hz, 1H), 13C NMR (125 MHz, DMSO-
d6): d 164.3, 150.1, 150.1, 149.3, 148.8, 146.9, 142.7, 140.7,
136.1, 134.0, 130.4, 129.5, 129.3, 129.3, 127.2, 127.2, 124.1,
122.2, 122.2; Anal. Calcd for C19H13ClN6O, C = 60.56;
H = 3.48; N = 22.30, Found C = 60.54; H = 3.47;
N = 22.29; EI MS m/z (% rel. abund.): 376 (M+, 59), 378
(M+2, 19).
2.6.27. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-(4-
hydroxy-3-methoxybenzylidene) benzohydrazide (31)
Orange solid, m.p. 264 C. Yield: (0.372 g, 88%); 1H NMR
(400 MHz, DMSO- d6): d 11.78 (s, 2H), 9.55 (s, 1H), 8.45 (s
1H), 8.43–8.36 (m, 3H), 8.09 (d, J= 6.8 Hz, 2H), 7.32 (s,
1H), 7.34 (d, J= 7.0 Hz, 1H) 6.85 (d, J= 7.0 Hz, 1H), 3.84
(s, 3H); 13C NMR (125 MHz, DMSO-d6): d 164.3, 148.8,
148.6, 148.3, 148.1, 148.1, 143.3, 136.1, 134.0, 130.4, 129.4,,5-b]pyridine benzohydrazide 4.
,5-b]pyridine benzohydrazones 5–34.
otential of novel imidazo[4,5-b]pyridine benzohydrazones. Arabian Journal of
Table 1 Synthesis of imidazo[4,5- b]pyridine benzohydra-
zones 5–34.
Comp. no. R Comp. no. R
5 20
6 21
7 22
8 23
9 24
10 25
11 26
12 27
13 28
14 29
15 30
16 31
17 32
18 33
19 34
Novel imidazo[4,5-b]pyridine benzohydrazones 7129.4, 127.8, 127.1, 127.1, 126.2, 122.5, 116.5, 115.0, 111.2,
56.7; Anal. Calcd for C21H16ClN5O3, C = 59.79, H = 3.82,
N = 16.60, Found C = 59.78, H = 3.81, N = 16.62; EI MS
m/z (% rel. abund.): 421 (M+, 41), 423 (M+2, 14).
2.6.28. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-(3-
hydroxy-2-iodo-4-methoxybenzylidene)benzohydrazide (32)
Yellow solid, m.p. 283 C. Yield: (0.481 g, 86%); 1H NMR
(300 MHz, DMSO-d6): d 12.10 (s, 1H), 9.74 (s, 1H), 8.73 (s,
1H), 8.44 (d, J= 2.4 Hz, 1H), 8.36 (d, J= 8.4 Hz, 2H), 8.31
(s, 1H), 8.10 (d, J= 8.4 Hz, 2H), 7.48 (d, J= 8.7 Hz, 1H),
7.08 (d, J= 8.7 Hz, 1H), 3.88 (s, 3H); 13C NMR (125 MHz,
DMSO-d6): d 164.3, 148.9, 148.8, 148.5, 148.2, 146.9, 142.7,
136.1, 134.0, 130.4, 129.5, 129.4, 129.2, 129.2, 127.1, 127.1,
124.1, 122.3, 117.6, 101.4, 56.7; Anal. Calcd for
C21H16ClN5O2, C = 62.15, H = 3.97, N = 17.26, Found
C = 62.14, H = 3.95, N = 17.24; EI MS m/z (% rel. abund.):
547 (M+, 74), 549 (M+2, 21).
2.6.29. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-
(2,5-dihydroxybenzylidene) benzohydrazide (33)
White solid, m.p. 285 C. Yield: (0.359 g, 88%); 1H NMR
(400 MHz, DMSO- d6): d 12.10 (s, 1H), 10.32 (s, 1H), 8.98
(s, 1H), 8.60 (s, 1H), 8.46 (s, 1H), 8.33 (d, J= 8.4 Hz, 2H),
8.11 (d, J= 8.4 Hz, 2H), 7.01 (s, 1H), 6.74 (d, J= 5.5 Hz,
2H); 13C NMR (125 MHz, DMSO-d6): d 164.3, 152.7, 151.2,
149.6, 148.8, 146.9, 142.7, 136.1, 134.0, 130.4, 129.5, 129.1,
129.1, 127.3, 127.3, 124.1, 122.0, 121.6, 118.1, 116.4; Anal.
Calcd for C20H14ClN5O3, C = 58.90, H = 3.46, N = 17.17;
Found C = 58.92, H = 3.47, N = 17.14; EI MS m/z (% rel.
abund.): 407 (M+, 57), 409 (M+2, 16).
2.6.30. (E)-4-(6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N0-
(3,5-dihydroxybenzylidene) benzohydrazide (34)
White solid, m.p. 289 C. Yield: (0.361 g, 89%); 1H NMR
(300 MHz, DMSO-d6): d 11.85 (s, 1H), 9.46 (s, 2H), 8.44 (s,
1H), 8.35 (t, J= 8.4 Hz, 3H), 8.27 (s, 1H), 8.07 (d,
J= 8.4 Hz, 2H), 6.61 (s, 2H), 6.27 (s, 1H); 13C NMR
(125 MHz, DMSO-d6): d 164.3, 158.2, 1258.2, 148.8, 147.9,
146.9, 142.7, 138.1, 136.1, 134.0, 130.4, 129.5, 129.3, 129.3,
127.2, 127.2, 124.1, 107.1, 107.1, 104.2; Anal. Calcd for
C20H14ClN5O3, C = 58.90, H = 3.46, N = 17.17; Found
C = 58.91, H = 3.45, N = 17.18; EI MS m/z (% rel. abund.):
407 (M+, 58), 409 (M+2, 18).
3. Results and discussion
3.1. Chemistry
The general synthetic pathway for the preparation of novel
imidazo[4,5-b]pyridine benzohydrazones 5–34 is shown in
Scheme 1 and 2. The first step involves synthesis of a methyl
4-(6-chloro-3H-imidazo[4,5-b]pyridin-2-yl)benzoate 3 which
was achieved by reacting 5-chloropyridine-2,3-diamine 1
with methyl 4-formylbenzoate 2. In this reaction, methyl 4-
formylbenzoate was treated with sodium metabisulfite to
form a sulfite adduct (In situ). This sulfite adduct was then
refluxed with diamine 1 in N,N-dimethylformamide for 6 h
to afford compound 3. The ester 3 was then converted into
benzohydrazide 4 by treating with hydrazine hydrate in metha-
nol for 6 h.Please cite this article in press as: Taha, M. et al., Antiglycation and antioxidant p
Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.08.004In Scheme 2, benzohydrazide 4 was reacted with various
benzaldehydes in the presence of acetic acid to form the final
derivatives 5–34.otential of novel imidazo[4,5-b]pyridine benzohydrazones. Arabian Journal of
Table 2 Various In vitro biological activities of benzimidazole derivatives 5–34.
Compound DPPH EC50 (lM± SEMa) Frap EC50 (lM± SEMa) Antiglycation IC50 (lM± SEM
a)
5 130.0 ± 0.15 159.56 ± 0.41 270.12 ± 0.15
6 NAb 1083.75 ± 0.07 286.12 ± 0.23
7 NAb 919.03 ± 1.2 392.12 ± 0.06
8 60.1 ± 0.41 504.66 ± 11.4 240.12 ± 2.3
9 NAb 934.83 ± 0.05 NAb
10 36.16 ± 2.1 114.35 ± 0.03 193.21 ± 0.04
11 33.12 ± 0.01 32.56 ± 0.15 230.12 ± 0.27
12 NAb 1339.87 ± 0.44 298.12 ± 1.4
13 80.12 ± 1.53 104.1 ± 1.7 NAb
14 32.64 ± 0.27 53.94 ± 0.81 260.12 ± 0.71
15 37.34 ± 0.31 100.89 ± 0.06 168.12 ± 0.03
16 NAb 1507.14 ± 0.57 NAb
17 NAb 1544.39 ± 1.8 NAb
18 NAb 399.85 ± 0.91 368.10 ± 0.1
19 90.12 ± 1.25 208.46 ± 0.05 316.12 ± 1.7
20 NAb 754.43 ± 0.26 NAb
21 NAb 1390.97 ± 0.64 NAb
22 NAb 770.11 ± 0.04 NAb
23 NAb 559.13 ± 0.15 NAb
24 NAb 975.65 ± 0.04 NAb
25 26.12 ± 0.15 281.96 ± 0.08 140.16 ± 0.36
26 42.12 ± 0.8 253.9 ± 1.4 412.16 ± 0.14
27 120.12 ± 1.29 404.94 ± 2.7 NAb
28 NAb 1519.73 ± 0.15 NAb
29 NAb 397.47 ± 0.04 311.6 ± 0.21
30 NAb 802.31 ± 0.49 420.12 ± 0.12
31 37.16 ± 0.45 164.18 ± 0.35 306.12 ± 0.02
32 45.02 ± 1.1 180.16 ± 4.5 370.12 ± 1.2
33 24.16 ± 0.25 101.75 ± 0.04 286.12 ± 0.5
34 29.14 ± 0.09 97.16 ± 0.71 392.12 ± 0.08
Gallic Acid 40.0 ± 0.12 119.63 ± 1.1 –
Rutin – – 294.46 ± 1.50
a SEM is the standard error of the mean.
b NA is the not active.
Figure 1 Hydrogen bonding between hydroxyl at ortho position
and nitrogen.
8 M. Taha et al.The crude products were further recrystallized from metha-
nol to afford pure compounds with the yield between 72% and
94%. The structures of the imidazo[4,5-b]pyridine benzohydra-
zones 5–34 were determined using spectroscopic techniques
such as NMR and MS and were further confirmed using
CHN analysis (see Table 1).
3.2. Antiglycation activity
In the continuation, of our work on bioactive compounds
(Rahim et al., 2015a and b; Khan et al., 2014a and b; Taha
et al., 2015d and e), Imidazo[4,5-b]pyridine benzohydrazones
(5–34) were synthesized and evaluated for their antioxidant
and antiglycation potential. The result for antiglycation shows
that IC50 values of the derivatives range between 140.16 and
420.12 lM (Table 2). Comparison between the IC50 values of
the derivatives with rutin (294.46 ± 1.50 lM) shows that some
of the derivatives are more potent than rutin. Among the
compounds which show potent activity are compounds 5, 6,
8, 10, 11, 14, 15, 25 and 33. Compounds 7, 12, 18, 19, 29,
30, 31, 32 and 34 displayed less than 50% inhibition. General
observation shows that the presence, number and position
of hydroxy group are essential to inhibit glycation process.
The most potent activity was displayed by compound 25
(IC50 = 140.16 ± 0.36 lM) which is a trihydroxy substitutedPlease cite this article in press as: Taha, M. et al., Antiglycation and antioxidant p
Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.08.004derivative displayed the most potent activity. Other hydroxy
substituted compounds which showed potent activity includes
compounds 8 (IC50 = 240.12 ± 2.3 lM), 10 (IC50 = 193.21
± 0.04 lM), 11 (IC50 = 230.12 ± 0.27 lM), 14 (IC50 =
260.12 ± 0.71 lM), 15 (IC50 = 168.12 ± 0.03 lM) and 33
(IC50 = 286.12 ± 0.5 lM). Good activity for compounds 10,
11 and 14 which are having hydroxyl groups adjacent to
each other might be due to the formation of through reaction
between hydroxy groups with the carbonyl group of
methylglyoxal.
As for compounds having single hydroxyl group, the result
shows that substitution at para position gives the best inhibi-
tory effect as compared to the other positions. It was also
observed that meta position gives the lowest inhibition activityotential of novel imidazo[4,5-b]pyridine benzohydrazones. Arabian Journal of
Figure 2 Hydrogen bonding for compounds 9 and 13.
Novel imidazo[4,5-b]pyridine benzohydrazones 9as compared to ortho position. The antiglycation activity for
hydroxyl substituted compounds shows that hydroxyl group
at ortho and para could easily form hemiacetal bonding with
methylglyoxal as compared to hydroxyl at meta position. This
is due to several factors such as steric hindrance, hydrogen
bonding and electron donating ability which could further sta-
bilize the compounds and prevent them from undergoing any
external interaction. There are some hydroxyl substituted
derivatives which are not showing good activity which includes
compounds 12 (IC50 = 298.12 ± 1.4 lM), 29 (IC50 = 311.60
± 0.21 lM) and 34 (IC50 = 392.12 ± 0.08 lM). The activity
of compound 12 which is having hydroxyl group at ortho posi-
tion might be low due to steric hindrance and hydrogen bond-
ing. As being observed in Fig. 1, the best orientation is
contributing significantly toward them the formation of hydro-
gen bonding between hydroxyl group and nitrogen of the
imine linkage which reduces the ability of the hydroxyl group
to interact with methylglyoxal (see Fig. 2).
The hydrogen bonding effect is also observed for com-
pounds 9 and 13 which are having thiophene and furan rings
respectively, where both compounds are not showing any inhi-
bition activity. However, hydrogen bond for compounds 9 and
13 is between their heterocyclic atoms with nitrogen of amide
moiety.
Observation on results for compounds 6, 7 and 30 having
pyridine ring displayed a contrasting effect as compared to
those being displayed by other compounds having heterocyclic
moieties. Compound 6 which is having a nitrogen atom at
ortho position possess the best activity as compared to other
compounds having nitrogen at meta and para position. This
strongly suggests that hydrogen bonding effect is absence for
compounds having pyridine ring and nitrogen at ortho position
helps to enhance the overall antiglycation activity.
The activity for compounds having methoxy does not show
much different when being compared to those having hydroxyl
group. Hence we could say that methoxy group does not play a
significant role in the inhibition activity. Other observation
includes the presence of heavy metals and halides. Comparison
between compounds 23 and 32with compounds having relevant
substitution reveals that heavy metal decreases the inhibition
activity significantly. On the other hand, compounds having
halide group (20, 23 and 27) do not show any inhibition activity.
3.3. Antioxidant
3.3.1. 1,1- Diphenyl-2-picryl hydrazyl Radical Scavenging Assay
(RSA)
The redox potential is very important in the oxidative activity.
The redox reaction is the mixture of two reactions occurs
simultaneously during oxidation and reduction. If thePlease cite this article in press as: Taha, M. et al., Antiglycation and antioxidant p
Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.08.004compounds have capacity to donate electron they will show
high activity, it means that they have good redox potential vice
versa. We see in the results the compounds having trihydroxy,
is most potent due to its redox potential to donate electron and
on the other hand compound having substituents not donating
electron showed very weak or no activity at all. Radical scav-
enging activity was evaluated for the synthesized compounds
and the results were compared with the standard Gallic acid.
The results of synthesized compounds indicated that com-
pounds 10, 11, 14, 15, 25, 31, 33 and 34 exhibited better radical
scavenging ability as compared to gallic acid (EC50 = 40.0
± 0.12 lM). Compound 25 which displayed the best antigly-
cation activity is among the compound which showed potent
radical scavenging activity with an EC50 value of 26.12
± 0.15 lM. It was found that compounds having more than
one hydroxy group have higher ability to scavenge radical.
Results indicate that none of the mono hydroxy substituted
compounds gives better activity when being compared to gallic
acid. But in some instances, single hydroxyl substituted com-
pounds do show good activity when being coupled with other
substituents. Compound 31 (EC50 = 37.16 ± 0.45 lM) which
is having methoxy displayed the lowest inhibition activity
among the compounds showing potent activity. Due to the fact
that other compounds having methoxy substitution are not
showing good activity, it can be concluded that methoxy group
in compound 31 does play a role in enhancing the ability of
hydroxyl group to participate in radical scavenging activity.
3.3.2. Ferric ion (Fe3+) Reducing Antioxidant Power (FRAP)
The reducing capability of the test compounds was evaluated
at different concentrations and the results were compared with
the standard Gallic acid. The analysis of the results showed
that compound 11 exhibited promising reducing power activity
with an EC50 value of 32.56 ± 0.15 lM. Besides compound 11,
there are other compounds showing potent activity as compared
to Gallic acid such as compounds 10 (EC50 = 114.35± 0.03 lM),
13 (EC50 = 104.1 ± 1.7 lM), 14 (EC50 = 53.94 ± 0.81 lM),
15 (EC50 = 100.89 ± 0.06 lM), 33 (EC50 = 101.75 ± 0.04 lM)
and 34 (EC50 = 97.16 ± 0.71 lM). Most of the compounds
which are potent activity for FRAP are having hydroxy
substitution. Surprisingly, compound 25 which is having
three hydroxy group is not showing good activity for FRAP
assay. Compounds having single hydroxy substitution are
also showing moderate to weak inhibition activity. Compound
13 which is bearing a furan substitution is found to be the only
compound with heterocyclic moiety to show good activity,
while other compounds with heterocyclic ring (6, 7, 9 and
30) show moderate to weak activity. The presence of methoxy
and halide groups does not play any significant role in enhanc-
ing activity for FRAP.otential of novel imidazo[4,5-b]pyridine benzohydrazones. Arabian Journal of
10 M. Taha et al.4. Conclusions
In conclusion, the synthesized imidazo[4,5-b]pyridine benzohy-
drazone derivatives having hydroxyl group are showing potent
antiglycation and antioxidative activity. The studies also
showed that the ability of some compounds to inhibit glyca-
tion is indirectly dependent upon their antioxidative capabili-
ties. The results suggest the compounds studied are possible
to play certain role in diabetic complication and oxidative
stress diseases.
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